HER3 activation leads to downstream PI3K/AKT pathway signaling, promoting cell survival and imparting resistance to EGFR-targeted therapies, which remains a cornerstone of treatment for EGFR-mutated NSCLC [106]. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.